Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating imatinib mesylate in patients with recurrent small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Small Cell Lung Cancer | Phase 2 | Status: COMPLETED